Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Azaserine, A New Tumour-Inhibitory Substance: Studies with Crocker Mouse Sarcoma 180

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Stock, C. C., Amer. J. Med., 8, 658 (1950); Reilly, H. C., Stock, C. C., Buckley, S. M., and Clarke, D. A., Cancer Res., 13, 684 (1953).

    Article  CAS  Google Scholar 

  2. Ehrlich, J., Anderson, L. E., Coffey, G. L., Hillegas, A. B., Knudsen, M. P., Koepsell, H. J., Kohberger, D. L., and Oyaas, J. E., Nature (see following communication).

  3. Bartz, Q. R., Elder, C. C., Frohardt, R. P., Fusari, S. A., Haskell, T. H., Johannessen, D. W., and Ryder, A., Nature (see following communication).

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

STOCK, C., REILLY, H., BUCKLEY, S. et al. Azaserine, A New Tumour-Inhibitory Substance: Studies with Crocker Mouse Sarcoma 180. Nature 173, 71–72 (1954). https://doi.org/10.1038/173071a0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/173071a0

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing